Table 1.
Clinical Characteristics of the Patients
| Variable | All Patients N = 913 | Symptomatic N = 617 | Asymptomatic N = 296 | P |
|---|---|---|---|---|
| Age (years) median (Q1–Q3) | 40.6 (23–55.6) | 41 (24–56.3) | 39.9 (20.4–52.5) | .086 |
| Sex (men) | 423 (46.3) | 289 (46.8) | 134 (45.3) | .671 |
| Dyslipidemia | 80 (22.2) | 63 (24.3) | 17 (16.7) | .124 |
| Hypertension | 124 (17.0) | 96 (19.0) | 28 (12.4) | .033 |
| Diabetes | 60 (8.2) | 49 (9.7) | 11 (4.9) | .029 |
| Cardiomyopathy | 55 (7.6) | 43 (8.5) | 12 (5.3) | .171 |
| Obesity | 42 (5.8) | 25 (5.1) | 17 (7.6) | .228 |
| COPD | 25 (3.4) | 20 (4.0) | 5 (2.2) | .277 |
| Active cancer | 17 (2.3) | 14 (2.8) | 3 (1.3) | .295 |
| Primary care center | 690 (75.6) | 416 (67.4) | 274 (92.6) | <.001 |
| Emergency department | 223 (24.4) | 201 (32.6) | 22 (7.4) | <.001 |
| Positive SARS-CoV-2 RNAa | 196 (21.5) | 156 (25.3) | 40 (13.5) | <.001 |
| Ct, median (Q1–Q3) | 24 (16–30) | 22 (16–29) | 28 (21–32) | .012 |
| Ct 0–20 | 78 (40.0) | 68 (43.9) | 10 (25.0) | .10 |
| Ct 21–25 | 29 (14.9) | 24 (15.5) | 5 (12.5) | |
| Ct 26–30 | 40 (20.5) | 28 (18.1) | 12 (30.0) | |
| Ct 31–35 | 40 (20.5) | 30 (19.4) | 10 (25.0) | |
| Ct >35 | 8 (4.1) | 5 (3.2) | 3 (7.5) | |
| Positive antigen (any NP-nasal-saliva) result | 120 (13.1) | 106 (17.2) | 14 (4.7) | <.001 |
| Positive NP antigen result | 118 (12.9) | 105 (17.2) | 13 (4.5) | <.001 |
| No. of days with symptoms | 3 (2–5) | |||
| Cough | 309 (50.1) | |||
| Fever | 289 (46.8) | |||
| Sore throat | 196 (31.9) | |||
| Nasal congestion | 193 (31.3) | |||
| Dyspnea | 115 (18.6) | |||
| Anosmia/ageusia | 53 (8.8)/44 (7.1) | |||
| Others: malaise/headache | 104 (17)/140 (23) |
Abbreviations: COPD, chronic obstructive pulmonary disease; Ct, cycle threshold of reverse-transcription polymerase chain reaction; NP, nasopharyngeal; RNA, ribonucleic acid; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
NOTE: Categorical variables are represented by number and (%).
aPerformed on nasopharyngeal samples.